Cystadenocarcinoma, Serous
"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
| Descriptor ID |
D018284
|
| MeSH Number(s) |
C04.557.470.200.025.480.240 C04.557.470.590.480.240
|
| Concept/Terms |
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 3 | 1 | 4 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma. Int J Gynecol Cancer. 2025 Mar; 35(3):101672.
-
Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 Oct; 34(10):1630-1638.
-
Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 10 07; 34(10):1630-1638.
-
Low-grade serous ovarian carcinoma: a brief overview of the histopathologic features and differential diagnosis. Int J Gynecol Cancer. 2024 Jul 01; 34(7):1109-1110.
-
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models. J Gynecol Oncol. 2025 Jan; 36(1):e4.
-
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma. Gynecol Oncol. 2024 07; 186:110-116.
-
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. Gynecol Oncol. 2022 Dec; 167(3):452-457.
-
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021 05 24; 12(1):3039.
-
Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma. PLoS One. 2020; 15(3):e0229569.
-
Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors. Gynecol Oncol. 2019 12; 155(3):429-435.